John A. Paulson
About John A. Paulson
Independent director of Bausch + Lomb (BLCO) since April 2022; age 69. President and Portfolio Manager at Paulson Capital Inc.; previously founded and led Paulson & Co. Inc., with prior senior roles at Gruss Partners and Bear Stearns. He holds a finance degree from NYU (1978) and an MBA from Harvard Business School (1980). In 2024 he attended 100% of Board meetings (8/8) and 100% of Nominating & Corporate Governance Committee meetings (4/4) .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Paulson Capital Inc. | President, Portfolio Manager, Director | Current | Investment strategy, mergers, event arbitrage, credit |
| Paulson & Co. Inc. | President, Portfolio Manager, Founder | 1994–prior | Founded firm; led investment activities |
| Gruss Partners | Partner | Prior to 1994 | M&A and investing |
| Bear Stearns | Managing Director, M&A | Prior to 1994 | Corporate finance, transaction execution |
External Roles
| Organization | Role | Status | Notes |
|---|---|---|---|
| Bausch Health Companies Inc. (BHC) | Chairman of the Board | Current (rejoined June 2022) | BLCO’s controlling shareholder; cross-directorship |
| Acadian Asset Management Inc. (formerly BrightSphere Investment Group plc) | Director; Chairman since April 2020 | Current | Public asset manager |
| Steinway Musical Instruments, Inc. | Chairman; majority owner | Private | Board leadership and ownership |
| P.F. Chang’s | Chairman; majority owner | Private | Board leadership and ownership |
| American International Group, Inc. | Director | 2016–2017 | Prior public company directorship |
Board Governance
- Independence: Determined independent under U.S. and Canadian rules; BLCO’s board is 90% independent (9 of 10 directors) .
- Committees: Member, Nominating & Corporate Governance Committee (Chair: Thomas W. Ross Sr.). Not on Audit & Risk, Talent & Compensation, or Science & Technology .
- Attendance: 2024 Board 8/8; Nominating & Corporate Governance 4/4; overall 12/12 (100%) .
- Executive sessions: Independent directors met in executive session at each of the four regular Board meetings in 2024 (presided by Lead Independent Director) .
- Tenure: Three full years of service as of March 24, 2025 .
Fixed Compensation
| Component (2024) | Amount | Detail |
|---|---|---|
| Board/Committee cash fees | $43,750 | Paulson elected RSUs for Q1–Q2; cash in Q3–Q4 per program |
| Annual equity retainer (RSUs) | $283,720 | 14,696 RSUs granted for 2024; grant-date fair value |
| Total BLCO director compensation | $327,470 | Sum of cash and stock awards |
| BHC director compensation (for service on BHC board) | $500,000 (stock awards) | Additional compensation from parent board |
Program structure for non-employee directors:
- $80,000 annual cash retainer; $240,000 target annual RSU grant; Lead Independent Director $40,000; Committee chair/member retainers (Audit chair $25,000; Nominating chair $15,000; Talent chair $20,000; members $7,500–$12,500); annual director total cap $750,000 .
Performance Compensation
Directors do not receive performance-based equity; RSUs are time-based. For context on BLCO’s pay-for-performance oversight (executive program):
- Annual Incentive Program metrics: Adjusted EBITDA (60%) and Revenues (40%); 2024 funding certified at 107% .
- PSU metrics: Organic revenue growth thresholds (4.5%→50%; 6%→100%; 7%→200%) and rTSR percentiles (30th→50%; 50th→100%; 80th→200%) .
- Outperformance PSU modifier (rTSR-based) and negative absolute TSR cap at 50% .
Other Directorships & Interlocks
| Company | Relationship to BLCO | Interlock Risk |
|---|---|---|
| Bausch Health Companies Inc. (BHC) | Controls 87.88% of BLCO shares (353,273,183 outstanding; BHC holds 310,449,643) | Paulson chairs BHC; cross-directorship may pose perceived influence on BLCO governance |
| Icahn Group agreement | Director Appointment & Nomination Agreement grants Icahn Designee rights over board seats/committee participation; constraints on rights plans | Heightened shareholder influence and structural constraints noted; not directly tied to Paulson but relevant to board dynamics |
Related-party oversight and transactions:
- Audit & Risk Committee reviews director conflicts; directors must recuse from voting on interested transactions .
- April 2025: BHC paid BLCO $14.7 million to terminate an indemnification arrangement under the Master Separation Agreement; otherwise no related-party transactions since Jan 1, 2024 .
Expertise & Qualifications
- Financial and investment strategy expertise (mergers, event arbitrage, credit) with SEC-registered firm leadership .
- Public company governance experience (BHC chair; AIG director; Acadian director/chair) .
- Education: NYU finance (1978), Harvard MBA (1980) .
Equity Ownership
| Metric | Value | Notes |
|---|---|---|
| BLCO common shares owned | 25,357 | As of March 24, 2025 |
| Vested RSUs (settlement deferred) | 7,687 | As of Dec 31, 2024 |
| Unvested RSUs | 14,696 | Annual equity retainer; vests prior to next annual meeting unless deferred |
| Total equity value at risk | $525,730 | Includes common shares and vested RSUs; excludes unvested RSUs/options |
| Ownership vs guideline | 131% of $400,000 requirement | Director guideline = 5× $80,000 cash retainer; compliance assessed |
| Ownership as % of shares outstanding | ~0.0072% (25,357 / 353,273,183 ) | Based on outstanding shares at 3/24/2025 |
| Hedging/Pledging | Prohibited; none of NEOs/directors hold margin/pledged accounts | Anti-hedging/anti-pledging policies; no exceptions for directors |
Governance Assessment
-
Strengths
- Independent status with perfect 2024 attendance and service on Nominating & Corporate Governance; signals strong engagement .
- Material personal ownership above director guideline; deferred RSU settlement enhances alignment .
- Board maintains robust governance practices (executive sessions; annual evaluations; independent compensation consultant; anti-hedging/pledging; clawbacks for officers) .
-
Potential red flags / monitoring points
- Cross-directorship: Chair of BHC, BLCO’s controlling shareholder (87.88%)—perceived influence risk; continue monitoring related-party arrangements and committee independence .
- Structural shareholder rights via Icahn Group agreement may constrain board actions and committee composition; consider implications for independent oversight .
-
Market/compensation signals
- Company say-on-pay support ~95% in 2024 indicates investor confidence in compensation governance (relevant to board oversight) .
- Company TSR since IPO: $90.30 vs peer group $93.86 as of 12/31/2024—neutral to slightly lagging; not attributable to any one director but relevant to oversight focus .
Appendix: Committee Assignments (2024)
| Committee | Members | Chair | Meetings |
|---|---|---|---|
| Nominating & Corporate Governance | Thomas W. Ross Sr.; Sarah B. Kavanagh; John A. Paulson; Andrew C. von Eschenbach, M.D. | Thomas W. Ross Sr. | 4 |
| Audit & Risk | Sarah B. Kavanagh; Nathalie Bernier; Gary Hu; Russel C. Robertson | Sarah B. Kavanagh | 8 |
| Talent & Compensation | Karen L. Ling; Gary Hu; Russel C. Robertson; Thomas W. Ross Sr. | Karen L. Ling | 6 |
| Science & Technology | Andrew C. von Eschenbach, M.D.; Nathalie Bernier; Gary Hu | Andrew C. von Eschenbach, M.D. | 4 |